CBL-B, His-Avi-Tag Recombinant

Catalog #

80414

$335 *

Size: 100 µg

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant human CBL-B (Cbl proto-oncogene B), encompassing amino acids 39-426. This construct contains an N-terminal His (6xHis) followed by an Avi-tag. The recombinant protein was affinity purified.

●

Synonyms

E3 ubiquitin-protein ligase CBL-B, Casitas B-lineage lymphoma proto-oncogene b, RING finger protein 56, RING-type E3 ubiquitin transferase CBL-B, SH3-binding protein CBL-B, Signal transduction protein CBL-B, RNF56, Nbla00127

●

Product Data Gallery

4-20% SDS-PAGE Coomassie Staining

Product Info

Storage and Usage

Citations

Species

Human

Construct

CBL-B (His-Avi-39-426)

Host Species/Expression System

E. coli

Purity

≥90%

Format

Aqueous buffer solution

Formulation

40 mM HEPES, pH 7.4, 120 mM NaCl, and 20% glycerol

48 kDa

Amino Acids

39-426

Genbank #

NM_170662

UniProt #

Q13191

Tag(s)

N-terminal His-tag, N-terminal Avi-tag

Background

CBL-B, a RING finger E3-ubiquitin ligase, acts as an intracellular checkpoint and a regulator of cytotoxic lymphocytes and NK cells. CBL-B binds E2-ubiqutin as well as target proteins such as TAM receptor TYRO3, forcing further degradation of TYRO3. CBL-B modulates innate immune responses and plays a key role in host defense to pathogens and anti-tumor immunity. Targeting CBL-B represents a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, tumors, and allergic airway inflammation. CBL-B has emerged as a new target of interest in the field of immunotherapy due to its ability to suppress cancer immune-evasion. CBL-B initiates anti-cancer immune responses in NK cells in both cytotoxic and effector T cells, promoting T-cell and NK cell activation.

References

1. Jeon, M.S., et al., Immunity. 2004; 21(2): 167-177.

2. Chiang, Y.J. et al., Nature. 2000; 403: 216-220.